Key Takeaways
- Ecovia Bio has closed a Series B funding round led by Pointe Angels.
- The funding will support expansion of manufacturing capacity at the company’s Livonia, Michigan facility.
- The company produces gamma polyglutamic acid (γ-PGA) biopolymers for cosmetics, agriculture, hygiene, and personal care.
- The company expects its Livonia facility to reach full operational capacity by 2028.
- Additional production sites are under evaluation to support long-term global demand.
Ecovia Bio Secures Series B Funding for Capacity Expansion
Ecovia Bio, a biotechnology company focused on biopolymer ingredients, announced the closing of a Series B funding round led by Pointe Angels, an independent angel investor group based in Michigan. The investment will be used to expand manufacturing capacity at Ecovia Bio’s Livonia facility in response to growing demand for its AzuraBase and AzuraGel product lines.
The company’s products are based on gamma polyglutamic acid (γ-PGA), a biodegradable biopolymer used across cosmetics, personal care, agriculture, and hygiene applications. According to Ecovia Bio, the expansion will support both near-term customer needs and longer-term supply commitments.
“We are excited to partner with Pointe Angels,” said Kousay Said, Chief Executive Officer of Ecovia Bio. “This capital enables us to meet immediate demand from our cosmetics, personal care, and agricultural customers while establishing the infrastructure needed to serve the hygiene sector at industrial scale.”
